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INTRODUCTION AND AIMS: Atrial fibrillation (AF) is the most common sustained
cardiac arrhythmia, the most devastating complication being thromboembolism
leading to fatal or disabling stroke. Although oral anticoagulation (OAC) is the
mainstay of prevention therapy in the general population, its benefit in chronic kidney
disease (CKD) patients is less well defined. End-stage renal disease patients treated with
vitamin K antagonists present increased risk of bleeding, accelerated cardiovascular cal-
cification and increased risk of calciphylaxis. Left atrial appendage closure (LAAC) is
performed to prevent complications in high-risk AF patients with contraindications to
OAC and in AF patients with events despite OAC.
AIM: To evaluate the efficacy and safety of LAAC in CKD patients with AF.
METHODS: Single-center registry of consecutive patients submitted to percutaneous
LAAC. All patients underwent a standardized clinical follow-up. The procedure details,
complications, CHA2DS2-VASc and HAS-BLED scores were registered. We used the
PROTECT-AF trial efficacy composite endpoint defined as the occurrence of stroke,
cardiovascular death or systemic embolic events, and the same trial’s composite safety
endpoint defined as the occurrence of procedure-related complications and major
bleeding events. CKD patients were defined as patients with estimated glomerular fil-
tration rate below 60 ml/min/1.73 m2 (using chronic kidney disease epidemiology col-
laboration equation). Statistical analysis included Mann-Whitney U test, chi-square
test, Cox univariate analysis and Kaplan-Meier survival analysis.
RESULTS: 92 patients were included (mean age 736 7 years, 59 male patients, 39
CKD patients). CKD patients presented statistically significant higher age (mean age 75
6 6 vs 726 7; p=0.02), higher CHA2DS2-VASc score (mean score 4.76 1.3 vs 3.96
1.3; p=0.007) and higher HAS-BLED score (3.66 0.7 vs 3.26 0.8; p = 0.047) than
non-CKD patients. During a mean follow-up of 9596 752 days, there were 3 strokes
in 3 patients (1 CKD patient; 2 non-CKD patients), 7 deaths (all non-cardiovascular)
and no additional systemic embolic events. Thus, the primary efficacy endpoint
occurred in 3 patients. Considering the primary safety endpoint, there were 3 pericar-
dial tamponades and 2 major bleeding in 5 patients (2 CKD patients, 3 non-CKD
patients). Thus, the primary safety endpoint occurred in 5 patients. The presence of
CKD did not predict the occurrence of the efficacy endpoint (p = 0,86) nor safety end-
point (p = 0,79) using Cox univariate analysis. There were no statistically significant
differences between CKD and non-CKD patients regarding either safety (Log Rank
0.065, p=0.79) or efficacy endpoints (Log Rank 0.03, p =0.86).
CONCLUSIONS: Percutaneous LAAC in CKD patients presented, in our cohort,
similar outcomes to non-CKD patients. The procedure can be considered as a treat-
ment option in this population.
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INTRODUCTION AND AIMS:Mild to moderate renal impairment affects 10% of
the population but it is difficult to detect because the disease is usually asymptomatic.
Patients with chronic kidney disease have an increased risk of myocardial infarction,
heart failure and death. Patients with severe renal dysfunction often have changes in
the structure and function of the heart. Previous reports show that also early renal
dysfunction is a risk factor for cardiovascular death, but it is unknown if the changes in
cardiac structure and function already exist in early impairment of renal function. The
study aims to investigate if there is an early link between kidney disease and cardiac
structural and/or functional changes.
METHODS: The population was selected fromMalmo¨ Preventive Project Re-
examination-study (MPP-RES). 1792 participants with mean age 676 6 were exam-
ined in 2002-2006 with echocardiography. Among other variabels we measured left
ventricular ejection fraction (LVEF), left atrial area indexed for body surface area
(LAA/BSA), peak myocardial velocity of the basal left ventricular wall in early (Em or
e´) and late (Am or a) diastole in the lateral and septal walls and doppler measurement
of peak velocity of blood flow through the mitral valve in early (Mitralis Emax) and late
(Mitralis Amax) diastole. Cystatin C was analysed in plasma and estimated glomerular
filtration rate (eGFR) with CKD-EPI formula was calculated. General linear regression
was used for statistical analyses. We included 1504 of the participants with no prior his-
tory of heart failure (HF), EF =>40% and eGFR based>15 ml/min/1,73m2. The partic-
ipants were then divided in 6 groups based on e-GFR levels =>90; 75-89,9; 60-74,9; 45-
59,9; 30-44,9; 15-29,9. 11,1 % av participants had eGFR =>90; 26,5% eGFR 75-89,9;
34,6% eGFR 60-74,9; 20,8% eGFR 45-59,9; 6,4% eGFR 30-44,9; 0,5% eGFR 15-29,9.
29,9% of the participants were women and 70,1% were men. We studied correlations
between e-GFR groups and echocardiography parameters (mean values from lateral
and septal walls). All analyses were adjusted for age, gender, hypertension, diabetes and
medication with renin angiotensin inhibitors. We looked at the whole group and per-
formed a subgroup analysis based on gender.
RESULTS: A significant correlation between eGFR groups and LAA/BSA, Mitralis
Amax and E/e´, respectively, was found in the total cohort (p=0,003, p=0.037 and
p=0.022). This correlation remains significant among men but not among women.
CONCLUSIONS: A significant correlation between early impairment of renal function
and functional and structual echocardiographic markers of early diastolic dysfunction
was observed. This supports our hypothesis that interaction between the heart and
kidney exists even in the early stages av renal impairment.
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